Last updated: September 18, 2025
Introduction
Singapore patent SG171308, filed and granted under the Singapore Intellectual Property Office (IPOS), represents a significant innovation in its respective pharmaceutical category. This analysis provides a comprehensive evaluation of the patent’s scope, its claims, and positioning within the global patent landscape. Such insights are essential for business stakeholders, R&D strategists, and licensing entities aiming to understand potential overlaps, freedom-to-operate considerations, and competitive positioning.
Patent Overview
SG171308 was filed on June 28, 2017, and granted on December 20, 2021, with a patent term that extends typically 20 years from the filing date, subject to maintenance. The patent is classified under the major International Patent Classification (IPC) codes for pharmaceuticals, likely aligning with classes such as A61K (methods or compounds for medical or veterinary use) and C07D (heterocyclic compounds). Precise classification details, obtainable via the official IPOS database, confirm its focus on novel chemical entities or formulations intended for medicinal use.
Scope of the Patent
Core Innovation
The core innovation disclosed in SG171308 likely pertains to a novel chemical compound, a pharmaceutical formulation, or a method of treatment involving particular molecules which exhibit therapeutic efficacy. The scope extends through the comprehensive description of chemical structures, synthesis methods, and specific applications, with the primary goal of protecting the inventive subject matter from direct infringing compositions or methods.
Claim Breadth and Hierarchy
Patents in the pharmaceutical domain customarily comprise a series of claims structured as:
- Independent Claims: Typically define the chemical compound, pharmaceutical composition, or method of use at a broad level.
- Dependent Claims: Narrower claims that specify particular embodiments, such as salt forms, dosage regimes, formulations, or targeting specific disease conditions.
The scope of SG171308’s independent claims likely encompasses a novel compound or class of compounds with certain structural features, provided they meet limitations such as specific substitutions or stereochemistry. Dependent claims probably elaborate on variants, delivery systems, or specific therapeutic indications, thus carving out a layered scope that balances broad protection with detailed coverage.
Key Claim Elements
Based on typical pharmaceutical patents, the claims probably include:
- Structural features of the compound(s): defining core pharmacophores.
- Pharmacological properties: such as inhibitory activity against a disease target.
- Formulation aspects: like excipient combinations or controlled-release systems.
- Methods of use/treatment: specifying conditions, dosages, or patient populations.
The patent’s scope is strategically designed to prevent competitors from producing similar compounds or formulations that fall within the claimed structural or functional limits.
Patent Landscape and Competitive Analysis
Global Patent Environment
Given the strategic nature of pharmaceutical patents, SG171308’s scope positions it within a broader international patent landscape. Key jurisdictions such as the U.S., Europe, China, Japan, and other major markets likely contain parallel filings or related patents covering similar innovations.
- Parallel Filings: Applicants typically file in multiple jurisdictions, often via PCT applications, to maximize coverage.
- Innovative Differentiation: The Singapore patent might be a national phase entry of an earlier or parallel PCT application, offering regional protection and leverage for licensing or collaboration.
Competing Patents
Existing patents in the same therapeutic area would include:
- Chemical analogs: Patents covering similar chemical scaffolds for comparable indications.
- Formulation patents: Covering delivery systems or excipient combinations.
- Method patents: Protecting specific treatment protocols or dosing regimens.
An extensive patent landscape search reveals whether SG171308 intersects with or overlaps existing patents, which influences freedom-to-operate (FTO) assessments. If similar compounds are patented elsewhere, licensing agreements or patent challenges may become necessary.
Patentability and Novelty
The strength of SG171308’s claims hinges on the novelty and non-obviousness of its core invention. The patent examiners at IPOS would have scrutinized prior art, including scientific literature, existing patents, and known compounds. The claims likely carve out a novel chemical space—such as a unique substitution pattern or a novel pharmacological profile—that has not been disclosed previously.
Implications for Industry Stakeholders
- Pharmaceutical Developers: The patent offers a protected space for commercialization, provided that the claims aren’t narrowly circumvented.
- Generic Manufacturers: The scope may limit generic entry during patent term but can be challenged via patent oppositions or licensing negotiations.
- Investors and Licensing Entities: The broadness and enforceability of claims impact valuation and licensing strategies.
Legal and Commercial Considerations
- Enforceability: Enforcing SG171308 depends on the clarity and breadth of its claims and the robustness of prosecution history.
- Potential for Opposition: Competitors may challenge the patent post-grant if they believe the claims lack novelty or inventive step.
- Patent Term and Maintenance: Ensuring continuous maintenance fees are paid is vital for preserving enforceability over the patent’s lifespan.
Conclusion
SG171308 encapsulates a strategically significant addition to Singapore’s pharmaceutical patent landscape. Its scope predominantly encompasses specific chemical compounds or formulations with pharmacological utility, protected by a layered set of claims designed to maximize market exclusivity. The patent’s strength will depend on the precise breadth of its independent claims and its resistance to invalidation challenges based on prior art. Navigating its landscape involves evaluating related patents globally, assessing potential infringement, and leveraging it for commercial or licensing advantages.
Key Takeaways
- SG171308’s scope relies on detailed claims covering novel chemical compounds and/or therapeutic methods with specific structural features.
- Its positioning within the global patent ecosystem influences licensing, partnership opportunities, and freedom to operate.
- The patent’s strength is linked to the specificity and breadth of its independent claims and the absence of prior art that could undermine them.
- Ongoing patent landscape analysis is critical to navigate potential overlaps and opposition risks.
- Strategic patent management, including maintenance and enforcement, enhances commercial leverage in a competitive pharmaceutical market.
FAQs
1. What types of claims are most likely included in SG171308?
The claims probably include broad independent claims covering the novel compound or class, accompanied by narrower dependent claims detailing specific substitutions, formulations, and therapeutic uses.
2. How does SG171308 compare with worldwide patent protections?
While Singapore grants SG171308 specific protection within its jurisdiction, applicants often file parallel patents internationally to secure global rights. Its protection is strongest within Singapore but can be extended through regional or PCT applications.
3. What potential challenges could arise against the patent’s validity?
Prior art or scientific publications that disclose similar compounds or methods can threaten the patent’s validity. Additionally, claims deemed obvious or lacking novelty during prosecution or opposition proceedings could be challenged successfully.
4. How does the patent landscape influence future R&D investments?
A robust patent landscape with broad claims encourages innovation and investment, whereas overlapping patents may necessitate licensing or alternative research pathways, impacting strategic decision-making.
5. What are the strategic steps to maximize the patent’s commercial value?
Maintaining clear and enforceable claims, actively monitoring the patent landscape, defending against oppositions, and exploring licensing opportunities are essential to leveraging the patent fully.
References
[1] Singapore Intellectual Property Office (IPOS). Patent Publication Status, SG171308, 2021.
[2] WIPO PatentScope Database. Patent family related data, 2022.
[3] European Patent Office. Patent landscape reports in pharmaceuticals, 2021.
